From the Journals

Hefty rewards pay off in smoking-cessation study


 

FROM NEW ENGLAND JOURNAL OF MEDICINE

A new study finds it pays to pay people to stop lighting up: Smokers were more likely to quit if they had an opportunity to gain rewards worth $600 than if they simply received free cessation aids or free e-cigarettes.

The wide majority of the more than 6,000 smokers in the randomized study didn’t quit despite offers of various incentives. All the same, “programs that offered financial incentives tripled the rates of smoking cessation, reduced employers’ costs per successful quit, as compared with programs that offered cessation aids alone, and yielded total costs that compared favorably with the costs of employing smokers,” the study authors wrote.

A snuffed out cigarette milosluz/istockphoto.com
The study, led by Scott D. Halpern, MD, PhD, of the University of Pennsylvania, was published online May 23 in the New England Journal of Medicine.

The researchers reached out to employees and spouses at 54 companies that use wellness programs provided by the Vitality Institute, which supports research into health promotion. The institute provided grant support for the study.

Just over 6,000 employees and spouses who smoked were assigned to five groups. One group received usual care. The others received interventions: free smoking-cessation aids (nicotine replacement therapy, bupropion, or varenicline); free e-cigarettes; up to $600 worth of an unidentified “reward incentive” plus free cessation aids; and up to $600 via a redeemable deposit, plus free cessation aids.

Participants could only get the entire reward incentive or the full $600 redeemable deposit if they showed signs of sustained smoking cessation via blood or urine test at 1, 3, and 6 months.

The median age in the groups ranged from 43 to 45 years, and most were not college graduates. Just over half were women, and roughly 90% said they wanted to quit smoking.

Pages

Recommended Reading

VIDEO: Addressing the opioid epidemic: Psychiatrists are poised to lead
MDedge Psychiatry
Marketing perks increased opioid prescriptions
MDedge Psychiatry
E-cigarette usage has changed
MDedge Psychiatry
Subcutaneous buprenorpine rivals sublingual for opioid use disorder
MDedge Psychiatry
FDA queries more companies about youth e-cig use
MDedge Psychiatry
Legalization of marijuana debate moving away from medical need
MDedge Psychiatry
Drug-related deaths continue to rise in United States
MDedge Psychiatry
VIDEO: Pills alone not the answer for pain management
MDedge Psychiatry
Alcohol abuse untreated in HCV patients, including HIV coinfected
MDedge Psychiatry
SAMHSA’s new general embarks on a new mission
MDedge Psychiatry